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Abstract: Despite enthusiastic advocacy for what personalized medicine might be able to 
deliver and major investments into the development of this, there remain disappointingly 
few examples of personalized medicine in routine clinical practice today, particularly in 
high areas of unmet need such as cancer. We believe that this is because personalized 
medicine challenges the moral, economic and epistemological foundations of medicine. In 
this article, we briefly describe the scientific premises underpinning personalized medicine, 
contrast these with traditional paradigms of drug development, and then consider the 
ethical, economic and epistemological implications of this approach to medicine. 
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1. Introduction 
The phrase ―personalized medicine‖ has become something of a ―term of art‖, which means 
different things to different people. One understanding of personalized medicine (PM) focuses on the 
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incorporation of molecular insights into treatment selection. Evolution of this form of PM has become 
a possibility because molecular biology has yielded extraordinary insights into the origins of diseases 
such as cancer and other chronic illnesses. These have revealed both the enormous heterogeneity and 
the clinical significance of a number of disrupted biological processes associated with development 
and progression of disease. Some have been linked directly with underlying genetic alterations, arising 
either at the time of conception (germ-line mutations) or during the life of an individual (somatic 
mutations). These advances, in turn, have led to the hope that PM will enable further progress in 
disease prevention, diagnosis and the delivery of tailored therapies. 
Yet, despite enthusiastic advocacy, major investments into the development of molecularly targeted 
agents and advances in diagnostic technologies, there remain few examples of these kinds of therapies 
in routine clinical practice today. It is therefore important to ask why progress in this form of PM may 
not (yet) have achieved its expected potential, and what might be standing in the way. 
We believe that despite being framed as an unproblematic scientific advance, this form of PM in 
fact challenges both the epistemological foundations of medicine and a number of fundamental moral 
and economic principles. While not all the issues we will discuss are unique to PM based on molecular 
diagnosis, they are particularly salient in this context. In this article, we briefly describe the scientific 
premises underpinning PM, contrast these with traditional paradigms of drug development, and then 
consider the ethical, economic and epistemological implications of this approach to medicine. 
2. Science of Personalized Medicine Based on Molecular Diagnosis 
As with other ―terms of art‖ a number of interpretations and definitions exist for PM, by the way it 
might both be practiced and what it seeks to achieve. Although the notion of patient-centric and 
individualized healthcare aligns well with the philosophy of PM, narrower contemporary definitions, 
such as the one crafted by a Harvard Medical and Harvard Business School meeting in 2006 typically 
specify ―the management of a patient’s disease or disposition by using molecular knowledge to 
achieve the best possible medicinal outcome for that individual‖ [1]. This narrower interpretation of 
PM, which is the one we will use in this article, assumes that interactions between drugs and protein 
receptors lead to modulation of signaling pathways that are associated with the development, 
maintenance or progression of disease. 
This ―biological modulation‖ may involve a native physiological process (via what we will term 
physiological targeting) or an aberrant process that is ordinarily absent in a healthy state. The latter 
strategy we will refer to as pathological targeting. Examples of physiologically targeted treatments 
include statins and angiotensin-converting-enzyme (ACE) inhibitors. Examples of pathologically 
targeted treatments include antibiotics and tyrosine kinase inhibitors (TKIs) used in cancer management. 
The effectiveness and toxicity profile of a drug (extrinsic biological factors) will depend upon the 
nature of interactions between the drug and, ―on-‖ and ―off-‖ target receptors (intrinsic biological 
factors). The nature of drug-receptor interactions (pharmacodynamic profile) and the drug’s movement 
into, within and out of the body (pharmacokinetic profile) will determine the duration and magnitude 
of effects and possible toxicities experienced by a patient. These pharmacodynamic (PD) and 
pharmacokinetic (PK) profiles may differ significantly between patients administered the same dose of 
drug due to genetic, physical, physiological and metabolic differences between individuals. 
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Thus, the practice of the form of PM based on molecular diagnostics would ideally recognize each 
patient’s unique PD and PK profile and attempt to tailor treatments for each individual. Identifying the 
presence of a pathological target is prerequisite for the implementation of a successful therapeutic 
strategy whereas the profiling of patients’ PD and PK profiles are critical to ensuring drug efficacy is 
not overshadowed by toxicity.  
3. Ethical Challenges of Personalized Medicine based on Molecular Diagnosis 
For PM, or indeed any other scientific, clinical or policy development to be embraced, it should be 
congruent with the moral dimensions of healthcare, the broader needs and preferences of patients, and 
the obligations of practitioners and policymakers. While it is beyond the scope of this article to discuss 
the moral dimensions of PM in detail, bioethicists who have written about PM have been concerned 
primarily with the extent to which a PM based on molecular diagnosis: (1) advances patient autonomy 
and agency; (2) promotes wellbeing; (3) prevents or minimizes harm; and (4) enables fairness and 
equity. These are well-recognized principles of biomedical ethics, but they play out in particularly 
interesting ways in the context of this kind of PM. 
At first glance it might seem that the premise of molecularly-targeted PM should easily align with 
the need to promote autonomy, do good and minimize harm. The acquisition of additional diagnostic 
knowledge for the purpose of predicting a positive treatment outcome, and the screening of patients for 
predictive molecular signatures associated with greater predisposition to drug toxicities, are 
fundamentally patient-centered approaches to healthcare. Both also provide additional information for 
decision-making, thus increasing the likelihood of benefit and decreasing the likelihood of harm. 
However the reality is more complicated as the potential also exists for a PM based on molecular 
diagnosis to both compromise patient autonomy and cause harm. 
Threats to autonomy are likely to arise if, for example, public or private insurers begin to coerce 
patients into having genetic tests as a determinant of coverage of medicines. As Vogenberg et al. argue [2]: 
“Whether an individual’s right to autonomy is primary and, therefore, a greater ethical 
requirement than society’s right to maintain efficient and effective care, or a payer’s right to 
avoid unnecessary cost burdens, remains problematic and illustrates a core issue in 
integrating PM into clinical care. Who should control access to new pharmacogenetic and 
pharmacogenomic tests and companion diagnostics?” [2]. 
In addition to threatening patients’ autonomy, the genetic tests associated with molecular diagnoses 
for PM pose all of the risks associated with genetic testing more generally, most notably potential 
breaches of confidentiality and subsequent genetic discrimination [2]. Harm might also stem from fact 
that it can be difficult to establish the safety of PMs. For reasons that will be discussed in detail below, 
personalized medicines can be difficult to test in clinical trials, so the ethical issues surrounding the use 
of innovative health technologies, with their often unclear and unpredictable risk—benefit ratios [3] are 
likely to be particularly significant in this context. 
With respect to justice, it might seem logical that strategies to facilitate selection of only those 
patients likely to benefit and/or experience lower toxicities would be a more cost effective approach 
compared to the empirical selection of treatments. The use of treatments that do not work wastes 
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resources, potentially exposes patients to costly adverse-effects, and delays time to effective treatment. 
Therefore funding only these treatments that are likely to work (and only the necessary companion 
diagnostics) go some way towards reducing waste in health systems. Also, because targeted therapies 
might be the only therapeutic option for particular individuals or sub-populations, the development of 
new PMs based on molecular diagnoses might promote equity amongst those patients with limited or 
clinically suboptimal options. 
However, this kind of personalized medicine poses a number of important challenges for those 
concerned with promoting justice, such as governments and insurance companies, who have to make 
decisions about distributing limited health care resources. 
This is because, while some molecularly-targeted PM strategies may be ―affordable‖ to those with 
sufficient means to pay for them, they are often expensive because companies want to recoup the costs 
associated with developing medicines that, by definition, are suitable for only a limited number of 
patients. Payers may, therefore, be asked to pay large sums of money for diagnostic tests and 
treatments that help only a small subset of the population. This is not necessarily a problem if these 
therapies are highly effective, but this is not always the case. 
In these situations, funding medicines not only creates significant opportunity costs, but also has the 
potential to conflict with and potentially undermine funding systems based on population-level cost 
effectiveness models. This was clearly illustrated by the events that unfolded when Australia’s 
Pharmaceutical Benefits Advisory Committee (PBAC) recommended against including trastuzumab 
(Herceptin) for the treatment of metastatic breast cancer on the national formulary, on the basis that it 
was not cost-effective. Public and medical lobbying that followed this decision was such that the 
government was pressured to set up a special fund, outside of the national formulary, to fund Herceptin [4]. 
This was the first time that the usual government funding system had been circumvented, and it is 
noteworthy that this event was focused on one of the most highly touted targeted therapies. 
It is also noteworthy that these events took place in a wealthy country, because threats to justice are 
even starker in low- and middle-income countries. In China, imatinib for CML costs approximately US 
$46,000 per year [5] while in India, trastuzumab currently costs approximately $US1,000 per month [6]. 
These prices are both well above the median salary in these countries, and because these countries are 
struggling to establish systems for universal health coverage [7] these medicines are currently 
available to only the wealthiest groups. 
While not all PMs targeted to particular diseases are expensive, or as morally and politically 
contentious as are targeted cancer therapies (and while, of course, these kinds of PMs are not the only 
health interventions with potentially high opportunity costs), situations such as those described above 
raise unavoidable questions about population-level cost-effectiveness, value and opportunity costs. The 
funding of molecularly-targeted PMs also places payers in a difficult ethical and political position as 
they struggle to balance efficiency with equity—weighing up their desire to help small (sub) 
populations of patients against their desire to allocate resources fairly to whole populations. 
4. Commercial Challenges of Personalized Medicine based on Molecular Diagnosis 
Because the kind of PM we describe seeks to provide optimal treatment for individuals, based on 
their molecular profiles, it cannot, by definition, lead to the development of drugs to treat entire patient 
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populations with apparently similar clinical conditions. PM of this kind thus challenges the traditional 
approach to drug development, where pharmaceutical companies have historically tried to develop 
drugs to meet a sizable ―volume of need‖ associated with common illnesses such as cardiovascular 
disease and asthma. Because of the societal burden of such diseases, payers have been motivated to 
purchase treatments for them, thus enabling companies to recoup development costs and make a profit, 
without the need for very expensive per patient treatments. These circumstances essentially describe 
the recipe for a ―blockbuster‖ drug, as illustrated by the success of Pfizer’s Lipitor [1,8] a drug that 
costs payers very little per patient per year but which has earned billions of dollars internationally for 
the company. This example is in contrast to the cost of personalized medicines, which generally cost 
payers many thousands of dollars per patient per year. In this regard, personalized medicines raise 
similar commercial issues to those raised by ―orphan‖ medicines used to treat rare diseases, where 
companies often charge large sums of money in order to make a profit. 
Personalized medicines that are based on molecular diagnostics also focus more on identifiable 
pathological targets rather than physiological ones. This is of commercial significance because patients 
who commence physiologically targeted drugs, such as bronchodilators and steroids used to treat 
asthma or lipid lowering agents used to treat hypercholesterolemia, often remain on treatment for the 
rest of their lives, thereby contributing to their status as ―blockbuster’‖ medicines. By comparison, 
pathologically targeted drugs generally may not need to be taken for extended periods of time, unless 
the disease concerned has progressed to the point of becoming intrinsically complex, highly evolved and 
molecularly heterogeneous, as with advanced cancer or HIV. However, the opportunity for longer-term 
maintenance therapy is also often limited due to the poor prognoses for patients with such diseases. 
There are additional exceptions, with some physiologically targeted medicines used only for short 
periods, e.g., analgesics. 
However, if a disease is appropriately diagnosed and molecularly characterized, pathologically 
targeted therapies—and thus many personalized medicines—may only need to be taken for finite 
periods of time as they limit the diseases ability to metabolically and physiologically maintain itself. 
An example being antibiotics selected for the management of bacterial infections due to in vitro 
sensitivities against the known pathogen. 
Whether treatment duration of pathologically targeted therapies are limited due to poor survival 
outlook or cure the opportunity to recoup investments into the development of pathologically targeted 
treatments is less. Thus, medicines of this type tend to be expensive in terms of their per patient costs. 
5. Epistemological Challenges of PM based on Molecular Diagnosis 
One of the reasons that PM based on molecular diagnosis is such a challenge for those developing 
and funding medicines is that it forces us to question contemporary biomedical views of evidence, 
including its generation and use in decision-making. In particular, this kind of PM challenges the 
primacy of the large phase 3 randomized controlled trial (RCT) (and by extension systematic reviews 
and meta-analyses) as the optimal means for generating evidence about safety and efficacy, and 
requires the consideration of more complex methods of analysis and more nuanced (and sometimes 
ambiguous) forms of data. In large measure this results from the co-dependent development, use and 
assessment of medicines and diagnostics and from the ethical imperative to allow crossover in trials of 
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personalized medicines. In this regard molecularly-targeted PM is similar to other paradigm shifts, 
such as the move towards ―learning organizations‖ that challenge traditional conceptions, both of 
evidence and the ethics of generating evidence. 
5.1. Challenges of Developing both Medicines and Co-Dependent Diagnostics 
One advantage of prospectively designed RCTs is that they control for a number of known and 
unknown biases that may influence study outcomes. This is achieved by randomization of patients into 
two or more treatment groups. One challenge with PM based on molecular diagnosis is that there are 
two rather than one intervention under assessment—both the treatment and the test for the relevant 
molecular biomarker. This, in turn, makes it particularly difficult to know what populations to select 
for comparison, and it may also lead to a requirement for double randomization as a way of evaluating 
the overall benefit or impact of taking a PM and co-dependent treatment strategy. 
5.1.1. Population Selection 
During early drug development, it can be difficult to know what populations to select for  
clinical trials. This is a particularly salient and complex issue in the testing of pathologically targeted 
therapies with the potential to become molecularly-targeted PMs. In clinical trials involving new 
physiologically-targeted drugs, it is generally fair to assume that all patients have the potential to 
respond to a new drug by virtue of them all possessing the same physiological target. This also means 
that any patient with the condition of interest could reasonably be included in a control group receiving 
an already proven physiologically targeted agent. In contrast, it may be much more difficult to 
establish what group of patients a pathologically-targeted PM should be tested against. 
Trials of trastuzumab for breast cancer illustrate this problem. On one level, it would seem most 
appropriate to measure the benefit of trastuzumab versus standard care only in a population of patients 
who have breast cancer cells expressing very high levels of the receptor targeted by trastuzumab 
(HER-2), as this would provide information about efficacy and safety in the population who would be 
expected to benefit. Payers, however, may want to know how all patients fare in clinical trials, as all 
patients will require testing, a cost that will have to be factored into cost-effectiveness analyses. Yet, 
even if it is decided that costs of testing need to be factored into cost-effectiveness analyses (and trials 
need to be designed accordingly), this leaves open the question of what weighting should be applied to 
test and drug in terms of their costs when determining overall cost-effectiveness. 
5.1.2. Double Randomization 
Merlin et al. have suggested two ways to overcome this ―problem‖, using a framework to help 
construct evidence for the cost effectiveness assessment of co-dependent health technologies [2,9],  
i.e., drugs associated with a co-dependent diagnostic test. Both methods involve double randomization.  
The first method involves the randomization of patients into either a diagnostic tested or non-tested 
group. Patients within both groups are then further randomized to either receive a new investigative or 
standard treatment. Thus patients with a known diagnostic status may be randomized to receive either 
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the new or standard of care treatment. Patients in the non-diagnostic tested group are also randomized 
to one of either treatment. 
The second, similar, method also involves randomization to, or not to, diagnostic testing. However 
patients categorized by biomarker status are assigned treatments accordingly, with patients known to 
harbor the predictive biomarker receiving the pathologically targeted treatment under investigation 
while patients not harboring it are allocated the standard of care. Alternatively, patients randomized to 
the non-diagnostic testing arm are further randomized to either treatment. 
Although Merlin et al. see these designs as providing ―high-level evidence‖ [9], it is difficult to see 
how RCTs designed in these ways would be accepted by human research ethics committees (HREC). 
For if a diagnostic test used to predict disease response and determine therapy is incorporated into a 
study design, then this, in itself, suggests a strong scientific rationale exists for using it. This, in turn, 
may lead an HREC to question whether there is sufficient equipoise to justify randomizing patients to 
no testing, or to view the treatment of patients with a known diagnostic status inappropriate if there is a 
lack of scientific justification for targeted therapies they may be assigned to. It would be unacceptable, 
for example, for the economic assessment of HIV testing and drug treatment to be assessed in this 
way, were it presented today as a potential new management paradigm. An alternative approach to the 
testing of ―co-dependent‖ technologies, that provides a balance between ethical imperatives and the 
need for scientific rigor, is therefore needed. 
One such approach might be to make use of historical or contemporary biomarker-defined patient 
cohorts from outside of clinical studies [2,10]. However this requires access to data collections and 
good quality bio-specimens linked with patient outcomes. These cohorts would also need to be 
matched as closely as possible to those entered into an RCT used in the evaluation of a drug’s relative 
efficacy and safety. Furthermore, from an ethical perspective, there would need to have been 
appropriately obtained patient consent that provides sufficient scope for research into known and 
future (but unknown at the time of consent) links between biomarkers and outcomes. 
5.2. Challenges in Demonstrating Value of Targeted Therapies 
A second epistemological challenge that arises with particular significance in the context of PMs 
based on molecular diagnosis is that it can be difficult to demonstrate survival benefit because of the 
ethical requirement to allow crossover [4]. This issue is particularly salient in the development of PMs, 
with their pathological targeting, especially when the control or standard of care is a physiologically 
targeted agent. In addition, knowledge of the pathologic pathway and mode of action of treatment 
together with emerging evidence from other studies showing evidence of benefit make for more 
compelling arguments to crossover, raising additional ethical issues for investigators and those wishing 
to interpret evidence for overall survival. The development of imatinib for the treatment of chronic 
myeloid leukemia (CML) illustrates this difficulty. 
The mainstays of therapy for CML had, up until the late 90s, been chemotherapy and bone marrow 
transplantation. Imatinib was developed with the knowledge that a dysfunctional enzyme, manufactured 
as a consequence of a mutation caused by the fusion of two separate regions of DNA (the 
―Philadelphia Chromosome‖), was at the heart of the proliferative signaling cascade that leads to  
CML [3,11]. Despite apparently impressive responses to imatinib observed in the clinical setting [4,12], 
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trials of imatinib were challenged in their ability to demonstrate the impact of treatment on patient 
survival. While this may have suggested that clinical impressions were somehow flawed, it was also 
possible that survival benefits in clinical trials were obscured by the fact that trials were not blinded, 
and patients crossed over from one arm to another in a non-random manner. 
To explain further, blinding of studies where one arm was chemotherapy was not possible and, 
because of this, patients with progressive disease who were not initially randomized to imatinib would, 
understandably, have been keen to commence treatment as soon as possible. In other words, early 
indications from interim study analysis and the lack of alternative treatment options created an ethical 
imperative to enable access to imatinib. The result was dilution of the overall survival signal as 
patients ceased chemotherapy and crossed over to imatinib therapy, either whilst still on trial or 
through compassionate access programs opened by the manufacturer Novartis [5,13]. 
While it is difficult to imagine a situation in which it would be ethically acceptable to force patients 
to remain on standard chemotherapy, payers still tend to base their decisions on survival endpoints 
demonstrated in RCTs. While reliance on such ―hard‖ historical endpoints is understandable, the 
possibility that this may lead to a failure to recognize real survival benefits is a source of major 
frustration to clinicians, patients and pharmaceutical sponsors seeking regulatory and reimbursement 
approvals [6,14]. In Australia, for example, the drug company, Roche have taken the decision not to 
seek public reimbursement of their BRAF targeted melanoma drug vemurafenib following its rejection 
twice by the Pharmaceutical Benefits Advisory Committee, despite melanoma being considered as 
―Australia’s‖ cancer, and despite vemurafenib being funded in other countries. 
6. Conclusions 
The realization of opportunities for healthcare provided by greater uptake of PM as defined in this 
article remains largely unfulfilled. While at first glance this might seem surprising given the enormous 
investment in the development of PM based on molecular diagnosis, and its congruence with the goal 
of patient-centered care, it is clear that PM of this kind also poses a number of ethical, economic and 
evidentiary challenges. Indeed, the barriers to uptake of PM are likely to be as much ―cultural‖ as they 
are ethical, economic or scientific in the sense that they threaten familiar social norms and values. 
There is nothing new about this—it has long been recognized that paradigm shifts that we come  
take for granted (such as the move towards ―evidence-based medicine‖) come about only through 
sustained efforts on the part of advocates to shift existing epistemic, moral and socio-political norms 
and values [7,15]. Understanding and accepting that ethical, economic and epistemic barriers exist,  
and that culture change will be required, must be the first steps towards promoting uptake of 
molecularly-targeted PM. The responsibility for this resides with those able to bring about change, 
including the pharmaceutical industry, its regulators and those paying for medicines.  
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